🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — July 21, 2026

Intuitive Surgical's Q2 2026 10-Q reveals a company firing on all cylinders, with total revenue surging 18.5% YoY to $2.89B and net income jumping 24.3% to $818.1M, driven by a 150 bps expansion in gross margins to 67.8%. The standout signal is the massive $1.44B in share repurchases during H1 2026, a 7x increase from the prior year, signaling extreme management confidence and a strong commitment to shareholder returns. However, this aggressive buyback has drained cash reserves, with cash and equivalents falling 18% from year-end 2025 to $2.76B, a key risk to monitor. Operating leverage is evident as income from operations grew 30.7% YoY, outpacing revenue growth, while operating expenses rose a more modest 13.0%. The absence of insider trading data or forward guidance in this filing limits visibility into management's near-term outlook, but the robust operational and capital allocation trends paint a bullish picture for this robotics leader.

1 high priority 1 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — July 21, 2026

The 29 filings for July 21, 2026, reveal a landscape dominated by corporate control events and significant insider ownership adjustments. The most material developments are the take-private of KORE Group Holdings at $9.25/share and the announced acquisition of Personalis by Tempus AI, both high-certainty catalysts. A notable cluster of insider activity is seen at ZeroStack Corp. (formerly Flora Growth), where three insiders—including the CEO—collectively control over 70% of shares and are incentivized by aggressive performance-based options tied to VWAP targets up to $17.85, a 250% premium to the exercise price. Passive institutional investors like Millennium Management and Royce & Associates are making measured, diversified bets, while a few filers (e.g., Dror Sherman at iPower) show rapid, opportunistic trading. The data suggests a bifurcated market: high-conviction insider moves in small/mid-cap names versus passive accumulation in larger, liquid names. No sector-wide margin or revenue trends are discernible from this set of filings, as they are primarily ownership disclosures rather than operating reports.

12 high priority 17 medium 29 total filings
· daily

S&P 500 Financials Sector SEC Filings — July 21, 2026

The S&P 500 Financials sector shows a bifurcated landscape in Q2 2026: property & casualty insurers (Chubb) and brokerages (Interactive Brokers) delivered strong core operating results with double-digit EPS growth, while diversified financial services firms (Marsh & McLennan) face margin compression and slowing underlying revenue growth. Capital One staged a dramatic turnaround from a year-ago loss to $3.0B net income, driven by a $662M loan reserve release and lower provisions. The sector is seeing significant debt capital markets activity, with Goldman Sachs and PNC collectively issuing $12B in senior notes, signaling opportunistic liability management and potential capital return capacity. Insider trading activity is notably absent across all filings, which is neutral but warrants monitoring. Key themes include: strong investment income tailwinds for insurers, credit normalization for consumer lenders, and a shift toward shareholder returns via buybacks (Marsh & McLennan H1 buybacks surged 152% YoY to $1.5B). The mixed sentiment across filings suggests selective positioning rather than broad sector conviction.

1 high priority 7 medium 8 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 21, 2026

The S&P 500 Industrials stream for July 21, 2026, reveals a sector bifurcated between operational strength and strategic transformation costs. 3M and Northrop Grumman both reported solid top-line growth (2.4% and 5.1% YoY, respectively) but experienced significant operating income compression due to large, one-time charges (divestitures, litigation, and contract adjustments), creating a 'mixed' sentiment profile. A key portfolio-level trend is the divergence between GAAP and adjusted metrics, with adjusted figures showing healthy margin expansion (3M +40 bps) while GAAP margins contracted sharply (3M -290 bps, Northrop -120 bps). The most critical development is the structural reshaping of FedEx, which completed the spin-off of FedEx Freight and changed its fiscal year, providing recast financials that show a strong 39.2% operating income growth in its core business. Insider activity was concentrated in Paychex, with a CFO sale and a director gift, but no pattern of concern emerges. The sector's forward-looking data is positive, with both 3M and Northrop Grumman raising full-year guidance, signaling management confidence in underlying business momentum despite near-term earnings noise.

6 high priority 3 medium 9 total filings
· daily

US Material Events SEC 8-K Filings — July 21, 2026

This digest covers 50 filings from July 21, 2026, revealing a market dominated by capital structure maneuvers, SPAC activity, and leadership transitions. The most significant themes are a wave of SPAC IPOs and business combination failures (FACT II, Twenty One Capital pivot), aggressive M&A in the consumer and defense sectors (Starco Brands, Innovative Aerosystems), and a notable number of distressed situations (Vicarious Surgical liquidation, Splash Beverage cash crunch). Period-over-period data was sparse in these event-driven filings, but where available, it showed strong performance (First Financial Bancorp record EPS up 8% YoY) alongside clear warning signs (Splash Beverage missed payments). Insider activity was limited, but the resignation of a director over a D&O insurance lapse at ClimateRock is a significant governance red flag. The overall sentiment is mixed, with a clear bifurcation between companies executing strategic growth and those facing existential challenges.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 21, 2026

The July 21, 2026 insider trading pulse reveals a day dominated by large-scale dispositions to the issuer at Cross Country Healthcare, where four top executives and directors collectively tendered over 886,000 shares at $13.25, signaling a potential capital return event or restructuring. Concurrently, a $44.9M disposition by ABRY Partners at KORE Group Holdings suggests a major PE exit. On the bearish side, notable open-market sales by the CTO of JFrog ($1.98M) and a 10% owner at Worthington Enterprises ($3.34M) raise caution flags. Positive signals are limited but include a director purchase at Wilson Bank Holding ($150K) and a TSMC VP buying $215K worth of shares. The day also saw significant equity awards at OSI Systems ($800K aggregate to four directors) and Imunon, alongside routine option exercises and RSU vestings. The overall sentiment is mixed, with a clear skew toward neutral events (gifts, awards, dispositions to issuer) but with several high-materiality bearish sales that warrant attention.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 21, 2026

The four Dow 30 filings for July 21, 2026, present a mixed picture of corporate health. 3M's Q2 results show a clear divergence between GAAP and adjusted performance: GAAP operating margins collapsed 290 bps YoY due to $619 million in special items (divestitures, litigation, restructuring), while adjusted margins improved 40 bps and adjusted EPS rose 11%. This gap, combined with a $2.99 billion treasury stock buyback that drained cash by 44%, signals aggressive capital return despite operational noise. Goldman Sachs issued $10 billion in long-term debt across three tranches (5.240%-6.215% coupons), a significant capital markets activity that suggests either opportunistic prefunding or balance sheet repositioning. Johnson & Johnson's insider sale of $5.79 million by an EVP, representing nearly 100% of her holdings after exercise, is a bearish signal from a senior executive. The key portfolio-level theme is capital allocation divergence: 3M is aggressively buying back stock while Goldman is issuing debt, and J&J insiders are selling. The most critical development is 3M's raised full-year adjusted EPS guidance to $8.80-$8.95, which, if achieved, would imply a forward P/E of ~17x based on current prices—a potential value opportunity if the adjusted earnings quality holds.

2 high priority 2 medium 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 21, 2026

The three filings in this digest all involve Nasdaq compliance issues, signaling a cluster of corporate distress among small-cap issuers. Origin Investment Corp I quickly resolved a technical audit committee deficiency, while Cypherpunk Technologies faces a more serious bid price deficiency with a 180-day cure period and potential reverse split. CN Healthy Food Tech Group Corp. received a delisting determination linked to CSRC review status, representing the highest materiality risk with an appeal deadline of July 23, 2026. No period-over-period comparisons, insider activity, or capital allocation data were available in these filings, limiting trend analysis. The overarching theme is regulatory and listing standard pressures, with CN Healthy Food Tech facing the most existential threat. Investors should monitor the appeal outcome and Cypherpunk's ability to regain compliance within the cure period.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — July 21, 2026

The July 21, 2026 filings reveal a day of extreme corporate distress and strategic realignment, dominated by a wave of insolvencies and liquidations. The most critical development is the liquidation of **Vicarious Surgical Inc.**, where stockholders are expected to receive nothing, and the Nasdaq delisting of **CN Healthy Food Tech Group Corp.**, which faces an existential appeal deadline. A significant cluster of three filings from **Simbhaoli Sugars Limited** shows its CIRP process finally moving forward after a stay was vacated, but the company remains deeply distressed with over ₹1.08 Cr in admitted claims. On the M&A front, **Gabriel India's** $98.44M acquisition of a 30% stake in HL Klemove India stands out as a high-growth bet on autonomous driving, while the **Bliss GVS Pharma** open offer at ₹299/share creates a potential arbitrage opportunity. The SPAC sector is active but troubled, with **FACT II Acquisition Corp.** terminating its deal and several others (Aeon, Horizon) taking on debt to fund searches. Period-over-period data from **MPS Limited** shows a strong 42.5% YoY net profit surge, while **Northpointe Bancshares** shows margin compression. The day's filings paint a picture of a market bifurcated between aggressive capital deployment for growth and the final throes of insolvency.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 21, 2026

Today's filings reveal a mixed picture with several high-profile SPAC transactions and corporate actions driving activity. Key themes include a significant SPAC merger valuing Terra Quantum at $3.5B, a contested tender offer for Lisata Therapeutics with financing issues, and a proxy fight at XAI Octagon over sub-adviser underperformance. Financial sector filings show mixed results: Synchrony Financial reported record purchase volume (+8% YoY) but earnings declined 8% due to higher provisions, while Cementos Pacasmayo posted strong EBITDA growth (+34.3% YoY) but margin contraction in cement. Insider activity was limited, with notable insider selling at KB Financial Group (largest shareholder reduced stake). Capital allocation trends include Energy Transfer's $1.75B debt issuance and Novo Nordisk's ongoing buyback. Several routine foreign issuer filings provided minimal new information.

10 high priority 40 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 21, 2026

All four filings originate from General Motors and its captive finance arm, GM Financial, making this a single-company deep dive rather than a broad sector overview. The overarching theme is a tale of two narratives: GM's operational strength (record EBIT-adjusted margins, raised full-year guidance, robust buyback activity) versus mounting credit stress in its financing unit (rising delinquencies, higher loan loss provisions, declining net income). Period-over-period comparisons reveal a 1.9% YoY revenue growth at the parent level, but net income attributable to stockholders plunged 31.1% YoY due to higher adjustments and tax expenses. GM Financial's net income fell 15-16% YoY, with the allowance for loan losses increasing 5.2% since year-end 2025, signaling deteriorating credit quality. The most critical development is the divergence between GM's raised EBIT-adjusted guidance ($14-16B) and the weakening consumer credit picture at GM Financial, which could pressure future earnings. No insider trading activity was reported in any filing, removing a key sentiment gauge. The portfolio-level pattern is a classic 'auto cycle tension' between strong manufacturing margins and rising consumer credit risk.

2 high priority 2 medium 4 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 21, 2026

The S&P 500 Healthcare sector shows a bifurcated landscape in Q2 2026: large-cap medical device and life sciences companies like Intuitive Surgical and Danaher are delivering strong operational performance, while insider activity at Johnson & Johnson raises concerns. Intuitive Surgical posted an 18.5% YoY revenue surge and 30.7% operating income growth, signaling robust demand for robotic surgery systems. Danaher reported a 60% YoY net earnings jump and raised full-year EPS guidance, though its Q3 core revenue guidance of 2.0%-3.0% suggests a potential deceleration from Q2's 3.0% actual. Eli Lilly's director stock awards are routine and non-material, while J&J's EVP sold $5.79M in stock after exercising options, a notable insider divestment. Cigna Investments' 13F shows a $485.8M portfolio heavily weighted toward tech giants, reflecting a cautious healthcare sector allocation. Key themes include margin expansion (Intuitive Surgical +150 bps gross margin), aggressive capital deployment (Intuitive's $1.44B buybacks vs $181M last year), and mixed forward guidance across the subsector.

7 high priority 2 medium 9 total filings
· daily

US Earnings Financial Results SEC Filings — July 21, 2026

The 20 filings for the period ending June 30, 2026, reveal a market characterized by divergent performance, with robust revenue growth in technology and industrial sectors (Intuitive Surgical +18.5%, Calix +24%, Danaher +57% net earnings) offset by significant margin compression and earnings declines in financial and consumer-facing companies (GM -31% net income, GPC -10.7%, Equifax -3.9% net income despite revenue growth). A dominant theme is aggressive capital allocation through share repurchases, with Intuitive Surgical ($1.44B), MSCI ($583M), and Marsh & McLennan ($1.51B) deploying substantial cash, often at the expense of balance sheet strength. Insider trading activity is notably absent across the filings, limiting one key signal source. The most critical developments include KKR Real Estate Finance Trust's widening net loss and dividend cut, Danaher's $9.8B acquisition, and the continued cash burn at pre-revenue companies like Tribal Rides and Conectisys Corp. Portfolio-level patterns indicate a bifurcation between companies successfully navigating cost pressures (3M, Danaher) and those facing rising expenses and credit losses (GM Financial, KKR).

20 high priority 20 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 21, 2026

The six DEF 14A filings reveal a mixed governance landscape, with two companies undergoing significant structural transitions. StepStone Group Inc. is transitioning from a controlled to a non-controlled company post-Sunset, requiring board independence changes by September 2026. Eagle Nuclear Energy Corp. faces a contested board election with three nominees for two seats, creating potential governance instability. Sunbelt Rentals and Co-Diagnostics show stable, routine governance with no material financial or compensation changes. AB CarVal and Embrace Change Acquisition Corp. are special-purpose vehicles with minimal executive compensation disclosures, offering limited actionable insights. No period-over-period financial trends, insider trading, or forward-looking guidance were disclosed across these filings, limiting quantitative synthesis. The key theme is governance risk and transition, with Eagle Nuclear's contested election being the highest materiality event.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 21, 2026

The IPO pipeline on July 21, 2026, reveals a stark contrast between a pre-revenue energy technology company attempting to go public and a clinical-stage biotech filing a registration for a potential reverse merger after a catastrophic regulatory setback. HNO International, Inc. is pursuing an IPO with zero revenue and mounting losses, relying on dilutive equity purchase agreements for survival, which signals a low-quality offering that may struggle to attract institutional demand. Passage BIO, Inc. is effectively filing a 'for sale' sign after its lead drug candidate PBFT02 was dealt a fatal blow by the FDA, triggering a 46% single-day stock collapse and a failed strategic review process where zero of three interested parties made an offer. The aggregate period-over-period data shows no revenue growth across either company (both have zero or de minimis revenue), while insider activity is absent from both filings, suggesting a lack of management conviction. The most critical development is Passage BIO's failed outreach to 148 counterparties, which strongly implies the asset has limited to no value and the S-4 is a precursor to a distressed merger or liquidation. The portfolio-level theme is a 'flight to quality' in the IPO market, where only companies with proven revenue and clear paths to profitability can successfully list, while speculative and pre-revenue companies face severe capital access constraints.

2 high priority 2 total filings
· daily

US SEC Trading Suspension Halt Orders — July 21, 2026

The three filings from July 21, 2026, reveal a concentrated wave of Nasdaq compliance and delisting actions affecting small-cap and micro-cap issuers, signaling heightened regulatory scrutiny on corporate governance, minimum bid price, and foreign issuer disclosures. Notably, two of the three companies face material threats to their listing status, with CN Healthy Food Tech Group Corp. receiving a direct delisting determination tied to CSRC review disclosures, while Cypherpunk Technologies Inc. is in a 180-day cure period for sub-$1.00 bid price non-compliance. Origin Investment Corp I quickly remedied its audit committee deficiency, demonstrating that governance gaps can be resolved swiftly. The aggregate data shows zero insider trading activity across all filings, suggesting management teams are not signaling conviction through personal transactions. No forward-looking guidance, capital allocation changes, or period-over-period financial comparisons were available in these event-driven 8-Ks, limiting trend analysis but amplifying the binary nature of the regulatory risks. The most critical development is CN Healthy Food Tech's July 23 appeal deadline, which will determine whether a full delisting and trading halt extension occurs, with material implications for shareholders of UCFI and UCFIW. The portfolio-level pattern is a clear uptick in Nasdaq enforcement actions against companies with governance gaps, low-priced stocks, and China-based operations facing CSRC scrutiny, creating both risk and potential catalyst-driven opportunities for active traders.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 21, 2026

The July 21, 2026, batch of 29 filings reveals a significant wave of board and C-suite transitions across US-listed companies, with a notable concentration in the technology, energy, and financial sectors. While most changes are routine governance moves, several carry high materiality, including a CEO succession at Twenty One Capital tied to a strategic pivot away from a business combination, a CFO appointment at Upland Software from a distressed turnaround background, and a CMO departure at Polaryx Therapeutics that the company claims will not impact clinical timelines. Period-over-period comparisons were sparse in these event-driven filings, but insider activity and forward-looking statements provide actionable intelligence: the CEO of Ferrellgas extended her contract signaling stability, while Jet.AI's board decision to avoid diluting shareholders by not accelerating PSU vesting is a clear positive for existing holders. A key theme is the separation of Chairman and CEO roles at Jerash Holdings to strengthen governance, and the use of stock-based compensation at Ecominas Corp. and Aware, Inc. to align management incentives. The most critical development is the D&O insurance lapse at ClimateRock that triggered a director resignation, a rare governance red flag that warrants monitoring for similar issues at other small-cap SPACs.

29 high priority 29 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 21, 2026

This digest of 29 USA Board Room Changes filings reveals a period of significant governance evolution, with a notable focus on financial expertise and strategic realignment. Key themes include the appointment of seasoned CFOs and financial leaders to boards (e.g., ExlService, MSA Safety, Blink Charging), a trend toward separating CEO and Chairman roles for improved governance (Jerash Holdings), and several C-suite departures signaling strategic pivots (Kemper Auto, Marriott Vacations). While most changes are routine, several carry high materiality, such as the CEO transition at Twenty One Capital and the CFO appointment at Upland Software, which are tied to specific strategic catalysts. The data shows a clear pattern of companies prioritizing financial discipline and operational efficiency, as evidenced by the appointment of directors with deep restructuring and capital allocation experience. The period-over-period comparisons, though limited in these filings, are supplemented by forward-looking statements and scheduled events that create a clear catalyst calendar for the next 30-60 days.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — July 21, 2026

The 18 filings reveal a bifurcated M&A landscape: SPAC activity is surging with three new IPOs (Samos Energy, Jones Ventures, AMR Resources) totaling $680 million in gross proceeds, alongside active deal financing (Aeon, Horizon Space) and advisory engagements (T-REX). However, this is tempered by notable failures—FACT II terminated its $175 million aerospace deal, and Vicarious Surgical is liquidating with zero expected recovery for stockholders. Operating company M&A shows mixed signals: Starco Brands' accretive acquisition of Custom Bakehouse ($20M revenue add) contrasts with Innovative Solutions' 1.5x revenue purchase of Aydin Displays, while Northpointe Bancshares' organic growth (MPP portfolio +36% YoY) is offset by margin compression (-11 bps YoY). Insider activity is sparse but negative, with Vicarious Surgical's entire board resigning and Flag Ship's auditor change flagged by material weaknesses. The overarching theme is capital rotation: SPACs are raising record sums but facing execution risk, while private equity take-privates (KORE Group) and targeted acquisitions signal selective value creation. No period-over-period comparisons were available for most filings, limiting trend analysis, but the data highlights a market favoring disciplined buyers over speculative SPACs.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 21, 2026

Overnight SEC filings reveal a mixed but cautious tone ahead of today's open, with a notable cluster of insider selling at high materiality levels. SharkNinja's CEO sold $38.8M in stock under a 10b5-1 plan, while Madrigal Pharmaceuticals' CEO exercised and sold options worth $372K, both generating bearish signals. The most critical development is an activist filing at Phunware, where Goldenwise Capital disclosed a 6.9% stake, publicly criticized governance, and threatened a proxy contest—the highest materiality event of the session. In the financial sector, Northfield Bancorp saw a wave of insider dispositions to the issuer, including the CEO returning 464K shares, suggesting a capital return event. On the positive side, Fulcrum Therapeutics saw a 10% owner buy $594K worth of stock, a bullish insider signal. Period-over-period data was limited in these filings, but the concentration of insider selling in biotech and consumer goods, combined with activist pressure at Phunware and a dilutive financing at VisionWave, points to a cautious market tone with select activist and insider-buying opportunities.

43 high priority 7 medium 50 total filings